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During the past years, several onconeural antibodies have been identified in association with a variety of paraneoplastic neurological disorders (PND). Many of them led to described PND. Some of them like anti-Yo or anti-Tr antibodies are clearly associated with one [1] neurological disorder (in this case, cerebellar ataxia). However, in many cases, whether these antibodies are associated with specific set of neurological symptoms or are only markers of the type of cancer remains unclear. Thus, there is a need to determine if a specific [1] [ 2] neurological syndrome occurs with a given antibody.
Anti-CV2/CRMP5 antibodies (CV2/CRMP5-Ab) were first described in a patient with cerebellar ataxia, peripheral neuropathy, uveitis and axillary lymph node metastasis of an undifferentiated carcinoma. Since this first description, the specific association of CV2/CRMP5-Ab [3] with PND has been confirmed in many other cases. CV2/CRMP5-Ab have been reported with PND involving different structures of the [4] [5] [6] [7] [8] [9] central and peripheral nervous system and small cell lung cancer (SCLC) is the most frequently associated tumor. These features seem to be very similar to the Hu-Ab-associated PND. Furthermore, both antibodies may occur simultaneously in a same patient and SCLC isthe [10] [ 4] most frequently associated tumor in both groups. However, it is not really known if the neurological symptoms differ or not between these 2 groups of patients. To address the specificity of the clinical presentation associated with CV2/CRMP5-Ab or Hu-Ab, we compared the clinical and tumoral features of patients presenting at least one of these antibodies.
METHODS
Patients
Data from patients with onset of the PND between January 1993 and December 2001 were retrospectively reviewed in the database of two centers: Rare Disease Reference Center for PND (Lyon-St-Etienne-Paris, France) and Barcelona (Spain). Clinical information on the neurological symptoms, severity of the neurological status, delay in the neurological diagnosis, tumor diagnosis and staging, and outcome of the patients were obtained from forms filled out by the referring neurologists, telephone interviews and review of the clinical records.
The clinical symptoms of the patients were coded into eight syndromes according to the published PND criteria: neuropathy (clinical [1] symptoms or electrophysiological evidences), cerebellar degeneration, limbic encephalitis, optic neuritis or retinitis (visual acuity alteration with papillitis oedema), myasthenic syndrome (myasthenia gravis or Lambert-Eaton myasthenic syndrome), chorea, dysautonomia and brainstem encephalitis. The neurological disability was evaluated by a modified Rankin scale. [11] Onconeural antibodies analysis
The patient sera were tested for the presence of onconeural antibodies by immunohistochemistry using paraformaldehyde fixed sections of adult rat brain and western-blotting. All sera were tested for Hu, Ri, Yo, CV2/CRMP5, Tr and amphiphysin antibodies. The presence of [4] CV2/CRMP5-Ab was affirmed when (1) the serum immunolabelled the cytoplasm of oligodendrocytes in the cerebellum and brainstem and (2) immunoreacted with the recombinant CRMP5 protein by western-blotting. , The presence of Hu-Ab was confirmed by Western blotting [6 8 ] using recombinant HuD protein (provided by Dr J. Dalmau, Philadelphia, USA).
While some of the characteristics of the two groups of PND patients were similar, neurological disorders associated with CV2/CRMP5-Ab did not parallel those associated with Hu-Ab ( ). Patients with CV2/CRMP5-Ab had significantly more frequent cerebellar ataxia (p than patients with Hu-Ab. In addition, the Rankin score at diagnosis was higher in patients with Hu-Ab than in patients with CV2/CRMP5-Ab.
In contrast, the frequency of limbic encephalitis was the same between the two groups. There was also no difference between the two patient groups concerning age, sex ratio or the cause of death.
Characteristics of peripheral neuropathy in CV2/CRMP5 patients versus Hu patients
In order to compare the characteristics of the peripheral neuropathy, an analysis was performed on a subgroup of 17 patients with CV2/CRMP5-Ab and 16 patients with Hu-Ab. These patients were selected because of the availability of a detailed clinical and electrophysiological analysis and because they were examined by one of the coauthors. In this subgroup, mean age (62.6 10.6 versus 61.6 10.8 Table 1 showed radiological evidence of lung cancer. The three patients with CV2/CRMP5-Ab without evidence of cancer were heavy smokers who were lost at follow-up less than 6 months after the onset of the neurological syndromes. PND led to the diagnosis of the tumor in 72.7 of ). SCLC was the most frequently associated tumor in both groups and thymoma was found only in patients with Table 1 CV2/CRMP5-Ab ( ). The other types of tumor observed in patients with CV2/CRMP5-Ab were undifferentiated carcinoma in 2 cases Table 1 (6.3 ), prostate small cell carcinoma in 1 case (3.1 ) and uterus sarcoma in 2 cases (6.3 ). In patients with Hu-Ab, the main other associated % % % cancers were lung adenocarcinoma in 19 cases (6.8 ), prostate small cell carcinoma in 7 cases (2.5 ) and gynecological cancer (breast, ovary, % % uterus) in 7 cases (2.5 ).
%
Clinical characteristics of patients according to the type of cancer
Neurological syndromes of CV2/CRMP5-Ab patients with malignant thymoma or SCLC were compared ( ). Patients with malignant Table 2 thymoma were significantly younger (p 0.05) than patients with SCLC and characterized by the more frequent association with myasthenia = gravis (p<0.01) and a less frequent association with neuropathy (p<0.01).
We also studied whether SCLC was associated with a particular clinical presentation depending on the type of antibody by comparing 21 patients with CV2/CRMP5-Ab, 196 with Hu-Ab and 7 with both antibodies. Differences were observed only for neuropathy (87.8 for Hu-Ab 
Survival analysis
The median survival time was significantly longer in patients with CV2/CRMP5-Ab than in patients with Hu-Ab or in patients with both antibodies (47.67 versus 11.46 and 18.00 months respectively, p 0.01) ( ). This difference was still observed when only the subgroup of patients with SCLC was considered (52.50 versus 11.53 and 18.00 months respectively, p 0.01) ( ). When adjusting for age, sex, Rankin
score and type of neurological symptoms in the SCLC patients group (Cox regression), the difference of survival time between patients with CV2/CRMP5-Ab, Hu-Ab and both antibodies was still significant (p 0.04).
=
Patients with both antibodies displayed a median survival time similar to that of Hu-Ab patients but seem to have a clinical presentation similar to that of the CV2/CRMP5-Ab patients with more frequent cerebellar ataxia and association with malignant thymoma ( ). Table 1 
DISCUSSION
The present analysis shows that CV2/CRMP5-Ab and Hu-Ab define two different profiles of paraneoplastic encephalomyelitis despite their apparent similar clinical and oncological features and their possible simultaneous occurrence in the same patient.
Comparatively to the Hu-Ab syndrome, the CV2/CRMP5-Ab syndrome is characterized by a high frequency of cerebellar ataxia, chorea and ocular manifestations including optic neuritis and posterior uveitis. Limbic encephalitis and diffuse encephalitis occur with the same frequency in both disorders. The neuropathy associated with CV2/CRMP5-Ab is also different from that of the Hu-Ab syndrome. The clinical and electrophysiological pattern of the Hu-Ab syndrome mainly corresponds to subacute sensory neuropathy as previously described , [10 12-14] and is frequently an isolated or a markedly predominant manifestation of the Hu-Ab syndrome. Conversely, the CV2/CRMP5-Ab neuropathy is frequently integrated in a more complex sensorimotor neurological disorder. Nerve lesions in patients with CV2/CRMP5-Ab probably account for the electrophysiological pattern of the neuropathy which is marked by a more severe axonal and mildly demyelinating pattern, although [15] motor nerve conduction velocities are also frequently mildly abnormal in patients with Hu-Ab. [16] Our results contrast with those of the Mayo Clinic group who reported a more unspecific neurological disorder in patient with CRMP5-Ab[ and only recognized chorea, optic neuropathy and retinopathy as clinical manifestation typical of CRMP5-Ab. , The same group also 9]
[9 17-20] suggested that, except anti-Yo/PCA1-Ab, all the other onconeural antibodies are frequently associated in a same patient and can only predict the presence of a tumor but not a specific neurological syndrome. The discrepancy between these results and ours may be explained by the [2] fact that we used the classical criteria for the definition of the neurological syndromes. These criteria were published in 2004 after Yu " " [1] et al publication. In addition, these authors used only Western blot analysis with recombinant protein and not immunohistochemistry for the [9] diagnosis of CV2/CRMP5-Ab. However, we observed a few patients with low titers of antibodies recognizing CRMP5 epitopes only by Western blot and which were not associated with PND. Anti-CRMP5 antibodies predict PND only if a staining of oligodendrocytes is [21] observed by immunohistochemistry. All these data demonstrate that the clinical analysis and the quality of data collection, like the [21] biological criteria used to define onconeural antibodies, are essential to study the relationship between onconeural antibodies and PNDs.
Another noteworthy result of our study, confirming previous reports, , is that CV2/CRMP5-Ab is associated mainly with SCLC and [4 9] thymoma. The association of CV2/CRMP5-Ab with thymoma is characteristic of this antibody. In our study, the long-term follow up of patients with thymoma excluded the possibility that an underlying SCLC had remained undiagnosed. Patients with thymoma and CV2/CRMP5-Ab were younger and developed more frequently myasthenia gravis and less frequently neuropathy than patients with SCLC. The clinical differences between thymoma and SCLC patients could reflect different mechanisms of immune reaction. Indeed, patients with thymoma frequently have immune responses against acetylcholine receptors or voltage-gatedpotassium channel while patients with SCLC may 
